Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study - Wikidata - awgldk - TriplyDB

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

http://www.wikidata.org/entity/Q33770347

about

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.'Acute myeloid leukemia: a comprehensive review and 2016 update'Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome.Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Acute myeloid leukemia: 2014 update on risk-stratification and management.Management of older or unfit patients with acute myeloid leukemia Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction.Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.Tetraspanin CD82 Regulates the Spatiotemporal Dynamics of PKCα in Acute Myeloid Leukemia Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.Total Body Irradiation without Chemotherapy as Conditioning for an Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia.Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells.The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.Upfront therapy of acute myeloid leukemia.How to manage high-risk acute myeloid leukemia.Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis.Frontline therapy of AML: should the older patient be treated differently?Acute myeloid leukemia: 2016 Update on risk-stratification and management.Acute Myeloid Leukemia: How Do We Measure Success?Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia.Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation.Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy.Recent developments in management of older patients with acute myeloid leukemia.New drug approvals in acute myeloid leukemia: what's the best end point?Treatment of acute myeloid leukemia in the elderly.De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.Acute myeloid leukaemia.

P2860

Q27851694-1FB92D29-1977-4E47-A88C-5F81C4603A80 Q28072539-F25F2F63-443F-4960-BBD2-3ECED2695B02 Q30249246-2366C504-1043-4228-9A93-7FD79D6398D5 Q33392185-28A55546-7C63-4B04-910A-7C2826D7ECD1 Q33598706-E356BDFF-6A7E-44FE-8A4A-A39CAE0AB046 Q33772415-4B55D9A5-7BE5-418C-A929-022EA5B5F272 Q33877213-7A6E825C-BB40-47F0-965C-2E53B7EF7BDD Q34193514-EB76877D-BA17-417B-B01C-54F4A0FC710E Q34194198-FF5F3247-32DD-449B-905B-019FAB5906F0 Q34350209-52B387E3-361D-4E8A-8579-70DCAAEC58BC Q34665691-5B29C765-BEDA-47F0-814A-0910F24F8806 Q34893307-19F5578F-BCD5-496E-903B-F9A0606A124A Q35864056-E5374CB3-6D36-4130-8F59-353B0C105DB7 Q36117062-FB8A4711-5DF7-424C-ACB2-7C735094C655 Q36208652-A3C2E1FB-BDB2-4E99-B1BD-7A8BD6C25157 Q36219674-451B0D80-1B98-4075-8967-1FD1C4E0697B Q36716744-9A68ECC6-31A1-4940-A5D0-7356AE58DB5C Q36914475-36C14730-6443-428E-8637-4A3CAE0C6259 Q36961604-5E7BFC1C-BCDF-45C1-89E2-5209B01E60A1 Q37096543-08AF86D6-D36E-48F6-9BFA-479C3F63DB3E Q37419348-86E7B6E6-890F-4E92-93DA-A41BAB12713A Q37443163-4653519F-E988-4DAB-9166-16FABBEC813E Q37591262-F3BF3F8E-8D1D-459D-9837-4C7830C2FFB3 Q37605585-B036E1ED-83D5-40DF-8D36-4BAFE2F91171 Q37897183-5CE08A28-966C-4B52-8897-06CF893823D1 Q37960820-312D3F7F-1BDA-4BEC-B604-777210110598 Q38044773-ABD3F395-01D2-41E6-951F-94191498EAEF Q38137208-ED95FD2C-3004-4B5F-B8E3-573BC13D49A9 Q38212586-70A44D74-DEAA-4D87-9454-2F517626A7AA Q38897289-3AE6D15F-3535-4864-955C-E86849ACF091 Q38948650-44B759D3-9274-4575-A0FD-41DE0013DE39 Q39706444-815030E3-9A40-4086-B000-543A74442C17 Q40370775-0F6D62F0-66E3-40B9-BC05-C233145273A2 Q40725017-4BBE7ABD-10DB-4983-8D67-0D1847CB0AFD Q42149211-A52ABF36-74C1-474E-9A46-F59FA98EE0FA Q42637732-8EEBC3FB-C9AB-4685-8B41-EB05B20DC2F2 Q42743023-4305B367-29DE-4ADD-B3A8-4334F175A139 Q43492386-DE6528B5-C588-4B67-B016-51BAC38A5C53 Q47156715-BE928E61-1927-44B8-81B1-B920DA5BB89B Q47432401-05D50563-8C8F-46BB-AB28-C9F41EC71F9A

P2860

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

http://www.wikidata.org/entity/Q33770347

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Effect of complete remission a ...... . Anderson Cancer Center Study

@ast

Effect of complete remission a ...... . Anderson Cancer Center Study

@en

type

label

Effect of complete remission a ...... . Anderson Cancer Center Study

@ast

Effect of complete remission a ...... . Anderson Cancer Center Study

@en

prefLabel

Effect of complete remission a ...... . Anderson Cancer Center Study

@ast

Effect of complete remission a ...... . Anderson Cancer Center Study

@en

P1433

Q33770347-850A52B2-57FE-4723-BE03-19494BF11BB1

P1476

Q33770347-773542BF-89DA-4D49-A94A-E4FC8D1DBC97

P2093

Q33770347-0D4C5CE0-9695-40AC-9FC3-0255877FC9AF

Q33770347-74A736CD-4226-438A-8B55-1637EE4AB068

Q33770347-7B24A69C-DD96-46F2-85B9-4DAB045C8707

Q33770347-DDE0C862-EE0E-4AE3-8443-C9793F407E38

Q33770347-EF80BBB4-9BD4-44EE-B8F9-AF719B11C975

Q33770347-F816E57A-E21A-4241-AA78-BB7FDA6EEC8E

Q33770347-FF3961C1-F4D7-49E7-B2C7-8A08C0A1321A

P2860

Q33770347-26C399F2-AD22-4D37-AAA0-EA98F133F2F6

Q33770347-3D4514F8-7C21-48AA-B3E3-C47488FAF86A

Q33770347-60FCFA10-DF01-4C9A-9E7E-50CE29D0E917

Q33770347-628F7D6B-17B2-447A-8F9E-D684D70C86A8

Q33770347-7B426983-4967-4857-9B67-7EB6E377B519

Q33770347-E43CC875-8C77-48C4-BAE6-E77B03DF6A93

P304

Q33770347-8507EB22-1138-409E-B9CA-21D277469256

P31

Q33770347-EA273056-2E53-42C4-9EB9-57A5F41C029F

P356

Q33770347-79770734-6540-4AFA-A02F-49BA8752B55D

P407

Q33770347-DC2450E6-9104-4497-97C9-48722EF2BCE9

P433

Q33770347-354BF212-CD11-46AE-AF18-09D2E1FBC44F

P478

Q33770347-7579CDB3-F79F-4004-ACBC-A7E3BB82190E

P50

Q33770347-58373AE1-AF73-4440-AF6E-BAFFC21EF3C8

Q33770347-7D4A79F0-5606-40B3-9371-6ABC5AE8250E

Q33770347-88DB60ED-BE7B-4917-9440-29CE5C0C5895

Q33770347-8F0154A7-5A79-4797-A4EB-6059E5BAB345

P577

Q33770347-396DAC9D-A2F6-4B66-9DA3-EB4923B0BB23

P698

Q33770347-6DDF0A3E-4DFD-4AEE-889D-81CD985EE05D

P921

Q33770347-A049ABA6-99C5-445F-A551-047C8D6944B3

P932

Q33770347-DCF3669B-8293-4787-980A-4B6C557F6F28

P356

JCO.2009.25.1066

P1433

Journal of Clinical Oncology

P1476

Effect of complete remission a ...... . Anderson Cancer Center Study

@en

P2093

Elihu H Estey

http://www.w3.org/2001/XMLSchema#string

Holly M Gundacker

http://www.w3.org/2001/XMLSchema#string

Roland B Walter

http://www.w3.org/2001/XMLSchema#string

Sherry A Pierce

http://www.w3.org/2001/XMLSchema#string

Stefan H Faderl

http://www.w3.org/2001/XMLSchema#string

Xuelin Huang

http://www.w3.org/2001/XMLSchema#string

Zhuoxin Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies.

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

P304

1766-1771

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.25.1066

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Martin S Tallman

Frederick R. Appelbaum

P577

2010-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20159819

http://www.w3.org/2001/XMLSchema#string

P921

P932

2849766

http://www.w3.org/2001/XMLSchema#string